Low-dose glucocorticoid improves progression-free survival of children with B cell acute lymphoblastic leukaemia following chimeric antigen receptor T-cell therapy
In the context of CRS/ICANS management, low-dose GC independently confers long-term PFS benefits to pediatric B-ALL patients without compromising CAR T-cell activity when using appropriate GC, TCZ, or RUX regimens.
Authors
- Shaoyan Hu (ORCID: https://orcid.org/0000-0002-5183-2259)
- Qi Ji (ORCID: https://orcid.org/0009-0002-6514-8586)
- Chonglian Qiu (ORCID: https://orcid.org/0000-0002-3819-9532)
- Xingqiang Dong
- Shuiyan Wu (ORCID: https://orcid.org/0000-0002-8963-5082)
- Jianwen Pan (ORCID: https://orcid.org/0000-0002-4123-698X)
- Hui Zhang (ORCID: https://orcid.org/0000-0002-7410-6516)
- Yuxuan Wang (ORCID: https://orcid.org/0000-0003-1028-2980)
- Jun Lu (ORCID: https://orcid.org/0000-0002-6740-6828)
- Zhenjiang Bai (ORCID: https://orcid.org/0000-0002-9404-7058)
- Saihu Huang
- Qinyi Zhang (ORCID: https://orcid.org/0000-0002-4809-5833)
Institutions
- Jiangsu Second Normal University (CN)
- Soochow University (CN)
- Children's Hospital of Suzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1604866
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu Commission of Health
- National Natural Science Foundation of China